Dahaba, Ashraf A. http://orcid.org/0000-0001-8513-3643
Bornemann-Cimenti, Helmar
Article History
Received: 22 July 2021
Accepted: 29 March 2022
First Online: 5 April 2022
Declarations
:
: As this was a single case report in one patient, a written informed consent to publish his information was obtained from our patient, and before both medications were stopped for the 2-week “migraine test period”. He also gave an additional informed consent that the simultaneous stopping of the 2 immunomodulators interferon and siponimod could expose him to either multiple sclerosis relapse or formation of new cerebral lesions.
: Both authors declare that absolutely no identifying images or other personal or clinical details of the participant are presented that compromise anonymity. They hereby confirm that written consent to publish this information was obtained from their study participant.
: Both authors state that they have absolutely no conflicts of interest (including financial, consultant, institutional and other relationships that might lead to bias or a conflict of interest). None of the authors received honoraria from a company or were on the speaker’s bureau for any organization, and there were no sources of financial support, corporate involvement or patent holdings other than departmental sources. There was no support from a pharmaceutical company or a manufacturer in any role such as editing of the protocol, drug supply, data analysis or writing of the manuscript.